Regulatory Affairs

FDA IND vs. Korean MFDS Clinical-Trial Plan Approval

A development-focused guide to the distinct US FDA IND and Korean MFDS clinical-trial plan approval pathways, with practical checks for nonclinical, CMC, and clinical documents.

1. Two distinct pathways: US FDA IND and Korean MFDS approval

The US and Korea both require regulatory review before most sponsor-initiated clinical investigations of an unapproved drug can begin, but the legal pathways should not be described as interchangeable. In the United States, the sponsor submits an Investigational New Drug application (IND) under 21 CFR Part 312. In Korea, the sponsor applies to the Ministry of Food and Drug Safety (MFDS) for approval of the clinical-trial plan under Article 34 of the Pharmaceutical Affairs Act and the MFDS Notice on Approval of Clinical Trial Plans. The Korean notice itself uses the term “IND application” in its definition, but the Korean statutory process is specifically an application for MFDS approval of a clinical-trial plan; calling it simply a US-style IND or a generic CTA can obscure the governing local requirements[1]; [3]; [4].

For a US IND, the investigation may generally begin 30 calendar days after FDA receives the application unless FDA places it on clinical hold, or earlier if FDA notifies the sponsor that the IND may proceed. This is not a general “approval letter” model. In Korea, the MFDS reviews the application and issues a clinical-trial-plan approval when it finds the submission acceptable; do not apply the US 30-day rule to the Korean process. Regulatory authorization is also distinct from institutional ethics review and site activation: the sponsor must separately confirm the applicable IRB/ethics approvals, qualified trial sites, contracts, and operational prerequisites before first participant dosing[1]; [3]; [5].

Planning pointUnited States — FDAKorea — MFDS
Primary legal framework21 CFR Part 312; IND content and conduct requirementsPharmaceutical Affairs Act, Article 34; MFDS clinical-trial-plan approval notice and applicable Enforcement Rule
Regulatory actionIND becomes effective after the statutory period unless a clinical hold applies, or FDA permits earlier startMFDS approval of the clinical-trial plan is obtained; an approval certificate is issued when the application is accepted
Submission strategyOrganize the IND around the applicable 21 CFR 312.23 content, including nonclinical, CMC, protocol, and investigator informationUse the current MFDS notice and its appendices to determine the required documents, scope, format, and any justified omissions
Ethics and site readinessIRB review/approval and investigator obligations remain separate from IND effectivenessConfirm the applicable IRB review, designated trial-institution requirements, and site-level readiness separately from MFDS approval

This comparison is a planning aid, not a complete legal checklist. Product type, study design, sponsor status, and applicable exemptions can change the required pathway. Confirm the current primary legislation and agency requirements before submission.

2. Non-Clinical Data: Toxicology and Pharmacology

A sponsor cannot simply test a chemical in humans based on an educated guess. The FDA mandates that the IND contain adequate information about pharmacological and toxicological studies conducted in laboratory animals or in vitro, providing a basis to conclude that human testing is reasonably safe[1]; [2]. This submission must include an integrated summary of toxicological effects and a statement declaring whether the studies complied with Good Laboratory Practice (GLP) regulations[1]; [2].

For Korea, the required package is determined using the current MFDS clinical-trial-plan approval notice, including its appendices and provisions for product-specific scope, requirements, and possible omissions[4]. For a US IND, 21 CFR 312.23 requires an integrated summary of relevant pharmacology and toxicology findings and a discussion of how the data support the proposed clinical investigation[1]. ICH M3(R2) provides a harmonized framework for timing and scope of nonclinical safety studies, but the package is not a one-size-fits-all checklist: study duration, route, dose, population (healthy volunteers versus patients), prior human exposure, and the nature of the investigational product all affect what is needed before a particular trial[6].

For small-molecule programs, genotoxicity testing is staged in relation to the planned clinical exposure and development phase; the familiar distinction between a limited package supporting certain early single-dose studies and a more complete battery before later-stage development should not be converted into a universal rule for every molecule or every Phase 2 start. Reproductive and developmental toxicity requirements are similarly linked to the population, inclusion of women of childbearing potential, duration of exposure, and applicable guidance. The practical task is to build a study-by-study nonclinical support matrix: proposed clinical population and exposure on one axis, completed or planned pharmacology, repeat-dose toxicology, toxicokinetics, genotoxicity, safety pharmacology, and reproductive/developmental studies on the other. Record the rationale and regulatory basis for each item that is not yet available; seek agency feedback where the proposed clinical exposure is not clearly supported.

3. Chemistry, Manufacturing, and Controls (CMC)

Demonstrating how a drug is made is just as important as showing what it does. Both the FDA and MFDS require comprehensive Chemistry, Manufacturing, and Control (CMC) data[1]; [2]. The FDA requires sufficient information to assure the proper identification, quality, purity, and strength of the investigational drug[1]; [2].

CMC expectations are phase-appropriate, but “phase-appropriate” does not mean that quality controls can be deferred without a safety rationale. FDA's current FIH Phase 1 CMC resource explicitly distinguishes information needed to assess quality and protect participants from selected information that may be submitted later. Examples of FDA-described flexibilities for qualifying FIH Phase 1 INDs include that clinical-lot stability data may not be required in some circumstances, initial stability data may not need to cover the entire proposed study duration, analytical method validation data are not expected, and process controls not directly related to product safety need not be specified at that stage. FDA provides separate detailed resources for small-molecule drug products and recombinant biological products; the applicable product-specific document should be consulted rather than applying these examples as blanket exemptions[7].

At every stage, the sponsor still needs enough information to support identity, quality, purity, strength, and safety of the clinical material. The CMC package should explain the drug substance and drug product, manufacturers and sites, composition, manufacturing process, relevant controls and specifications, analytical methods, batch information, container closure, storage conditions, and stability support appropriate to the proposed study. For sterile products, sterility, endotoxin/pyrogen, and particulate controls are especially important. Any difference between the clinical material and the material used in pivotal nonclinical studies should be identified and scientifically assessed. FDA's CMC page also makes clear that the required amount of information varies with development phase, formulation, and study duration[7].

CMC topicFIH Phase 1 planning questionDevelopment implication
Identity and compositionCan the clinical batch be unambiguously identified and its composition explained?Uncertainty about what is administered is a core quality and participant-safety issue, not a routine deferral.
Manufacturing and control strategyAre the manufacturing process, critical materials, and safety-relevant controls described?Prioritize controls linked to product quality and safety; document why other controls are not yet needed.
Specifications and analytical methodsAre acceptance criteria and test methods suitable to release and characterize the clinical material?Do not interpret the FIH flexibility on method validation as permission to release material without fit-for-purpose quality testing.
Stability and container closureDoes available stability information support the proposed storage, preparation, and dosing period?If full-duration data are not yet available under an applicable FDA flexibility, define ongoing stability commitments and controls.
Nonclinical-to-clinical comparabilityIs the clinical batch sufficiently comparable to the material used in toxicology studies?Assess changes in process, formulation, impurity profile, route, and exposure for potential impact on relevance of the nonclinical package.

Important: FDA's FIH CMC flexibilities are FDA-specific and product-specific. They should not be assumed to apply automatically to an MFDS submission or to later-phase INDs. For Korea, check the current MFDS notice and applicable product-specific requirements.

4. Clinical Protocols and the Investigator's Brochure

The core of the clinical strategy is defined by the study protocols and the Investigator's Brochure (IB). The FDA requires an IB to be provided to each participating investigator before the study begins[1]; [2]. The IB serves as a comprehensive manual containing a summary of the drug's pharmacological and toxicological effects, pharmacokinetics, and any previous human experience[1]; [2].

For an FDA IND, a protocol is required for each planned clinical study. FDA's current protocol resource emphasizes that early-phase protocols should clearly define safety-critical elements, including toxicity monitoring, dose-adjustment rules, stopping rules, and adverse-event collection and reporting. For Phase 2 and 3, the protocol should provide detailed efficacy and safety methods, endpoint rationale, patient selection, assessments, and prespecified contingencies for anticipated design changes[8]. These requirements should be reflected in the operational documents used by sites, not just in the protocol synopsis.

The Investigator's Brochure (IB) should provide investigators with a coherent summary of the clinical and nonclinical information relevant to the investigational product. Before submission, reconcile the IB, protocol, Investigator's Statement or local investigator documentation, pharmacy/manual instructions, informed-consent materials, and safety-management plan. Pay particular attention to the starting-dose rationale, dose-escalation or dose-modification rules, DLT definition and observation window (where applicable), stopping criteria, prohibited concomitant medications, pregnancy precautions, and handling of serious adverse events. Inconsistencies across these documents can create review questions and, more importantly, operational risk at the study site.

Toolkit Tip: Our Human Equivalent Dose (HED) Calculator can provide a body-surface-area-based conversion of an animal NOAEL to an estimated human-equivalent dose. HED is only one input to dose selection: it is not, by itself, a safe starting dose or a substitute for selecting the relevant species, evaluating the toxicology and pharmacology package, applying an appropriate safety factor, and following applicable regulatory guidance.

Practical Review Checklist: Before an IND or Korean Clinical-Trial Application

Use this as an internal completeness check, not as a substitute for the applicable regulation or a regulator's advice. Requirements depend on the product, development stage, study design, and jurisdiction.

  • Product identity and quality: confirm the investigational product, dosage form, manufacturing process, specifications, stability data, and control strategy are described consistently across documents.
  • Nonclinical support: map each proposed starting dose, route, schedule, and target population to the relevant pharmacology and toxicology evidence; document unresolved risks.
  • Protocol and investigator information: check that eligibility criteria, dose escalation or stopping rules, safety monitoring, adverse-event handling, and informed-consent materials agree with one another.
  • Jurisdiction-specific package: maintain separate FDA and MFDS checklists for forms, submission routes, language, local institutional review/ethics steps, and required attachments. Do not assume that satisfying one authority automatically satisfies the other.
  • Traceability: assign an owner and version/date to each document, resolve cross-document inconsistencies, and record the rationale for any item that is not yet applicable.

Common review traps

A technically complete dossier can still be difficult to review if dose rationale, manufacturing controls, safety monitoring, and protocol language contradict one another. For a live submission, verify the current text of 21 CFR Part 312 and the current MFDS rule and annexes; regulations and agency expectations can change.